Healthy Women Image

Monica Mallampalli, PhD, MSc

Founder and President of Institute for Women’s Health Strategies

CEO, Alliance of Sleep Apnea Partners

Monica Mallampalli, Ph.D. is a trained biomedical scientist and brings a unique perspective to women’s health — from science and research to policy and advocacy. Dr. Mallampalli considers herself a women’s health advocate. Using the lens of sex and gender differences, she has brought attention to knowledge gaps in science and policy in several areas of women’s health, including chronic pain, sleep health, cardiovascular health, musculoskeletal health, autoimmune disease, mental health, breast cancer, Alzheimer’s disease, urological health and clinical trials.  Dr. Mallampalli has authored many research papers and opinion articles, and has been interviewed by the media on multiple occasions. 

Previously, Dr. Mallampalli served as the senior scientific advisor at HealthyWomen, where she brought national attention to women and chronic pain, and she now serves as the chair of HealthyWomen’s chronic pain advisory council, which she established in 2020. Prior to HealthyWomen, Dr. Mallampalli served as the vice president of scientific affairs at the Society for Women’s Health Research (SWHR). Dr. Mallampalli has also worked at the National Institutes of Health as a Health policy analyst and as a research fellow. She obtained her post-doctoral fellowship at the Johns Hopkins University School of Medicine’s Department of Cell biology.

She earned her Ph.D. at the University of Utah in Human Genetics and received a Master of Sciences with a concentration in biochemistry from Osmania University in India. Dr. Mallampalli is the founder and CEO of the Institute for Women’s Health Strategies focused on applying data-driven strategies and solutions to advance and improve the science of women’s health. Currently, she serves as the executive Director at the Alliance of Sleep Apnea Partners (ASAP).

Full Bio
The CRISPR Nobel Prize Is a Win for Female Scientists: Will It Be a Win for Women’s Health?

The CRISPR Nobel Prize Is a Win for Female Scientists: Will It Be a Win for Women’s Health?

The lack of diversity in biomedical sciences research hurts women

Women's Health Policy

Genes are like a recipe for a soufflé: If one instruction is missing, it can cause a big problem. But with genes, the stakes are much higher than just being embarrassed in front of your mother-in-law. A single error in the double helix of the human genome's four-letter DNA alphabet can cause a debilitating disease.

Earlier this year, Emmanuelle Charpentier and Jennifer Doudna shared the Nobel Prize in Chemistry for developing a revolutionary gene-editing tool called CRISPR-Cas9 (CRISPR). Nearly as revolutionary is that this was the first Nobel Prize in science shared by two women.

CRISPR-Cas9, which functions like a spellchecker, elegantly repairing DNA so that genetic code can once again read as it should, works even better than previous generations of CRISPR. Over the last decade, the technology has allowed researchers to alter genes to fight cancer and treat a range of other diseases, from HIV to blood disorders.

A lack of women in biomedical sciences research

Since 1901, the Nobel Prizes and the Prize in Economic Sciences have been awarded to 930 people and 25 organizations, yet only 57 of these individuals have been women. In total, only 22 Nobel Prizes in the sciences have gone to women. This is a big problem, as recognizing more women, involving them in the scientific discussions of the day and funding their research could have major implications for women's health.

We've known for decades that increasing gender diversity in the biomedical sciences leads to increased attention on women's health issues. For example, researchers started spending more time on health conditions that affect women, such as breast cancer and autoimmune disease, only after more women entered academic research in the 1980s and 1990s.

The number of women who receive research doctoral degrees in the U.S. has doubled since 1997; nonetheless, marked disparities still exist. A 2019 study, for example, showed that women with no female peers are less likely to graduate within the typical six years than males in their same program.

While there is agreement that women make crucial contributions to scientific research, the biomedical research workforce lacks gender diversity and doesn't currently reflect the United State's population.

How to move the needle on gender diversity

If we include women not only as researchers, but also center them as participants in studies, I believe we will start seeing even more benefits to women's health.

A 2019 study that reviewed sex data from tens of thousands of published articles and clinical trial records determined that women made up 49% of participants in clinical trials. Despite this even representation, the study also showed that sex biases against female participants in clinical studies persist. For instance, although many females were represented in articles and records for digestive disease and musculoskeletal disorders, they were underrepresented in studies for certain disease categories, including HIV/AIDS, chronic kidney disease, mental disorders, neurological disorders and respiratory diseases.

CRISPR-Cas9 gives us an exciting opportunity to keep moving the needle in the right direction. Earlier this year, CRISPR technology was used to develop a test that detects the virus that causes COVID-19 in a matter of minutes. And there are vast possible therapeutic applications, including treating conditions such as blindness and HIV and using it as a promising targeted gene therapy approach for triple-negative breast cancer, an aggressive, often terminal, disease that accounts for 12% of all breast cancers. Imagine the wide range of diseases and conditions we can focus on, including some of the ones that still fall victim to sex biases, if we continue to get women involved and supported in the sciences.

Striving toward true inclusion

Before Charpentier and Doudna received this year's Nobel Prize in Chemistry, in 2016, they were both awarded a L'Oréal-UNESCO For Women in Science International Award. This award is given every year to female researchers addressing some of the world's biggest challenges, and it helps position women as leaders in their respective scientific fields. Such accomplishments serve as stepping stones to success, providing women with the resources to continue their work.

The importance of the CRISPR tool Charpentier and Doudna developed demonstrates the magnitude of contributions women can make to science. Prominent recognition for their accomplishment, like winning a Nobel Prize, helps to bring attention to the fact that we need to break down barriers that prevent women from becoming leaders in their respective areas of science.

Diversifying the biomedical field has been shown to be an essential component of equitable science, and more women than ever are receiving recognition for their work. The gene-editing tool Charpentier and Doudna created has the power to rewrite life as we know it.

It's thrilling to consider how their work — and the work of other female researchers waiting in the wings for recognition — may positively contribute to women's health.

You might be interested in